Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer

Understanding the biology of breast cancer is important for guiding treatment strategies and revealing resistance mechanisms. Our objectives were to investigate the relationship between previous systemic therapy exposure and mutational spectrum in metastatic breast cancer and to identify clinicopath...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2018-01, Vol.89, p.64-71
Main Authors: Fujii, Takeo, Matsuda, Naoko, Kono, Miho, Harano, Kenichi, Chen, Huiqin, Luthra, Rajyalakshmi, Roy-Chowdhuri, Sinchita, Sahin, Aysegul A., Wathoo, Chetna, Joon, Aron Y., Tripathy, Debu, Meric-Bernstam, Funda, Ueno, Naoto T.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Class I Phosphatidylinositol 3-Kinases - genetics
Female
Genes, p53
Humans
Middle Aged
Mutation
Neoplasm Metastasis
Next-generation sequencing
PIK3CA
Proto-Oncogene Proteins c-akt - genetics
PTEN Phosphohydrolase - genetics
Somatic mutations
Systemic therapy
TP53
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Understanding the biology of breast cancer is important for guiding treatment strategies and revealing resistance mechanisms. Our objectives were to investigate the relationship between previous systemic therapy exposure and mutational spectrum in metastatic breast cancer and to identify clinicopathological factors associated with identified frequent somatic mutations. Archival tissues of patients with metastatic breast cancer were subjected to hotspot molecular testing by next-generation sequencing. The variables that significantly differed (P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2017.11.015